BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesCompany update

SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its participation in the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8 in Colorado Springs, Colo. Through a special industry-sponsored session, "Inspired by

Related news

NBIXNeurocrine Biosciences2026-11-05 13:30 EST

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules

NBIXNeurocrine Biosciences2026-10-12 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-10-15 12:00 EST

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

ALKSAlkermes plc2026-11-05 12:00 EST

Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

HRMYHarmony Biosciences2026-11-04 12:30 EST

Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

XENEXenon2026-09-21 20:01 EST

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

AXSMAxsome2026-09-17 11:00 EST

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

PRAXPraxis Precision Medicines2026-10-27 20:01 EST

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

View all latest news

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

NBIXNeurocrine Biosciences2026-11-05 13:30 EST

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules

NBIXNeurocrine Biosciences2026-11-03 21:05 EST

Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress

NBIXNeurocrine Biosciences2026-11-02 21:49 EST

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-10-30 12:30 EST

Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia

NBIXNeurocrine Biosciences2026-10-26 12:30 EST

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

Stock data

Close
159.76 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States